Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Respiratory Syncytial Virus
Interventions: Nasal swab sampling, Blood sampling, Diary cards; Procedure · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 6 Years
Enrollment: 2,409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 9
States / cities: Oakland, California • Sacramento, California • Santa Clara, California + 5 more

Conditions: Painful Intermetatarsal Neuroma (Morton's Neuroma)
Interventions: CNTX-4975, Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Castro Valley, California + 10 more

Conditions: Stroke
Interventions: Hip exoskeleton, Baseline; Device · Other
Lead sponsor: Georgia Institute of Technology; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Graft vs Host Disease
Interventions: Atorvastatin calcium; Drug
Lead sponsor: Mehdi Hamadani; Other
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Morgantown, West Virginia • Milwaukee, Wisconsin

Conditions: Bunion, Hallux Rigidus
Interventions: 0.5% ropivacaine, Exparel; Drug
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Columbus, Ohio • Westerville, Ohio

Conditions: Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification
Interventions: Nivolumab, Capecitabine, Oxaliplatin; Drug
Lead sponsor: Kidney Cancer Research Bureau; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoporosis
Interventions: Automated follow up; Behavioral
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 55 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Osteosarcoma, Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Malignant Peripheral Nerve Sheath Sarcoma, Malignant Fibrous Histiocytoma of the Bone, Chondrosarcoma of the Bone
Interventions: Endurance, Strengthening, Stretching, Home exercise program; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Typhoid
Interventions: Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of of 1.7 x 10^10 CFU (Cohort 4), Placebo (Cohorts 1-4 pooled); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: South Miami, Florida • Baltimore, Maryland • Burlington, Vermont

Conditions: Acute Musculoskeletal Pain, Chronic Pain
Interventions: Educational Video, Telecare, Correspondence with Primary Care Provider; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Aging
Interventions: Sulforaphane, Narrow-band Ultraviolet B exposure, 4 mm skin punch biopsy; Drug · Radiation · Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hearing Loss, Hearing Loss, Sensorineural, Cochlear Hearing Loss
Interventions: Diagnostic tests of cochlear implant or acoustic hearing function, Targeted aural rehabilitation of the poorer performing ear; Diagnostic Test · Behavioral
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Bethesda, Maryland • College Park, Maryland

Conditions: Essential Tremor, Parkinson's Disease (PD), Dystonias
Interventions: Normal therapeutic DBS, Reduced current DBS, Reduced frequency DBS; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 90 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Barth Syndrome
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 5 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Crohn Disease
Interventions: Diet Counseling, CD LFD, Dyadic Psychological Support (DPS); Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Knee Osteoarthritis, Synovitis of Knee
Interventions: 4P004, Placebo (NaCl 0.9%); Drug
Lead sponsor: 4Moving Biotech; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Tucson, Arizona • Chicago, Illinois • Burlington, Massachusetts

Conditions: Phenylketonuria
Interventions: SAR444836; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more

Conditions: Chronic Kidney Disease
Interventions: Group 2: Dasatinib, Group 2: Quercetin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Coronary Artery Disease
Interventions: Antigravity treadmill (Alter-G), Conventional treadmill/regadenoson; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Osteoarthritis, Knee
Interventions: Low dose radiotherapy, Sham comparator; Radiation · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 100 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Interventions: TRC253; Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 2 more

Conditions: Healthy Volunteers
Interventions: Evacetrapib, Warfarin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: ITI-214, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Search by objective public record fields.

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Adaptive Hip Exoskeleton for Stroke Gait Enhancement

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

Effectiveness of Automated Inpatient Endocrinology Consultation for Osteoporotic Hip Fracture

Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Reducing the Transition From Acute to Chronic Musculoskeletal Pain Among Older Adults

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure

Optimizing Bilateral and Single-sided-deafness Cochlear Implants for Functioning in Complex Auditory Environments

Attention and Eye Movement in Parkinson's Disease

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

Diet Intervention for Crohn's Disease Patient

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

Senescence in Chronic Kidney Disease

Anti-gravity Treadmill Exercise in Stress Myocardial Perfusion Imaging

A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients

Radio- KO Radiotherapy for Knee Osteoarthritis Clinical Trial

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement